EGFR and non-small cell lung carcinoma: The study compared pemetrexed maintenance with erlotinib maintenance in non-squamous non Epidermal Growth Factor Receptor (EGFR) mutated non-small cell lung cancer (NSCLC). The study was an open label, single centre, parallel, phase 3 randomized study with 1:1 randomization between maintenance pemetrexed arm and erlotinib arm. 351 patients were screened, 151 patients screen failed and 200 patients were enrolled.